Bio-Rad Laboratories, Inc.Class A (BIO) — 分析摘要
Bio-Rad Laboratories, Inc.Class A(BIO)的市值为7.96十亿美元,最近一年的营收同比增长了+0.7%。净利润率为29.4%。当前市盈率为47.2倍。
核心要点
- 营收同比变化+0.7%
- 净利润率29.4%
- 市盈率47.2倍
与LABORATORY ANALYTICAL INSTRUMENTS板块的其他公司相比,BIO的营收增长为+0.7%,市盈率为47.2倍。
Bio-Rad Laboratories, Inc.Class A (BIO)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 1.2x — 偿债缓冲极低
净利润较上一期下降 77.8%。
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
行业
LABORATORY ANALYTICAL INSTRUMENTS
员工人数
7,450
总部
HERCULES, CA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。